R.E. Port
Estimating Individual Pretreatment Levels Of A Pharmacologic Response Variable
|
Dinesh de Alwis and Leon Aarons
The Population Pharmacokinetics Of Ondansetron: A Covariate Analysis
|
Mentre F. (1), Comets E. (1), Pousset F. (2), Plaud B. (2), Diquet B. (2), Montalescot G. (3), Ankri A. (4), Mallet A. (1), Lechat Ph. (2)
Population Pharmacokinetics/ Pharmacodynamics Of Fluindione In Patients.
|
M. Audran(1) , F. Bressolle (2), R. Gareau (3) and R. Gomeni (4)
A Population Pharmacodynamics Model Of Recombinant Human Erythropoietin In Athletes
|
R.C. Schoemaker, J. Burggraaf & A.F. Cohen
Assessment Of Liver Blood Flow Using A Continuous Infusion Of A Drug With High Hepatic Clearance
|
Bruce NJ, Thomson AH, †Undre N, †Stadler P, Elliott HL.
Assessment Of Covariate Relationships In The Analysis Of The Population Pharmacokinetics Of Tacrolimus.
|
Janet R. Wade
Presentation Of Population Analyses For Regulatory Submissions
|
Laveille C. a), Le Coz F. b), Lerebours G. a), Resplandy G. a), and Jochemsen R. a)
Population Pharmacokinetics Of A New Bradycardic Agent In Healthy Male Volunteers: Influence Of Food And Time Of Administration
|
Farkad Ezzet & Jeffrey Eisele
Inter-Occasion Variation In The Bioavailability Of Benflumetol (An Anti Malarial Drug)
|
D.Santos Buelga; M.E.Mendez*; M.J.Garcma; M.Pardo*; A.C.Falcao**; A.Dominguez-Gil.
Population Pharmacokinetics Of Tobramycin In Neonates
|
P. Girard, L.B. Sheiner
A Population Markov Model For Analyzing Dose History
|
Pascal Maire, Roger W. Jelliffe, Xavier Barbaut, Nathalie Bleyzac, Bruno Charpiat, Christine Pivot, Eliane Vermeulen, Pierre Ducrozet, Marie-Aude Confesson, Alain Laffont,
Individualized Drug Therapy And Population Modeling
|
Mats O. Karlsson1, Tarja Naukkarinen1,2 and Hans Lennernds1
A Population PK/PD Model For The Anti-Parkinsonian Triple Therapy: Levodopa (Ld), Dopadecarboxylase (Ddc) Inhibitor And Catechol-O-Methyl Transferase (Comt) Inhibitor
|
E. Niclas Jonsson and Mats O. Karlsson
XPose - An S-Plus Based Model Building Aid For Population Analysis With Nonmem
|
France Mentre, Alain Mallet
Optimal Design In Population Pharmacokinetics
|
P.Milligan, M.Karlsson, D.Nichols
Experiences With CYP-2D6 Polymorphism In Clinical Drug Development
|
Nguyen L, Bastian G, Doz F, Urien S, Peng B, Chatelut E, Boddy AV, Newell DR, Rubie H, Houin G, Canal P
Prospective Evaluation Of A Formula To Predict Carboplatin Clearance In Children
|
N.J Rahman,J.C Wakefield,C.Falcoz,
Incorporation Of Population Pharmacokinetic Principles Into Drug Development
|
Willi Weber, Lutz Harnisch, Christian Rokitta, Jonathan Collins, H.-Juergen Roethig
Leflunomide Populationpharmacokinetics And Its Interaction With Activated Charcoal/Cholestyramine
|
Stuart Beal, Ph.D.
Simulating PK/PD Trials
|
Stuart Beal, Ph.D.
A Preview of NONMEM Version V
|
Dr. Guenther Strehlau
POPKAN Demonstration
|
Dr. Hariolf Schmid (1), Dr. G. Strehlau (2)
Probability Statements About Predicted Kinetic/Dynamic Profiles In Population Analyses
|
Roberto Gomeni
VISUAL-NM (Version 1.0)
|
Saïk Urien
MP2 (V 2.0) A Windows® Application For Population Pharmacokinetics
|
Marie Gårdmark, Mats O Karlsson and Margareta Hammarlund-Udenaes
A Pharmacokinetic Model For Morphine Incorporating Acute Tolerance And M3G Interactions
|
Farkad Ezzet
Population Pharmacokinetics Of Valsartan
|
T Bouillon MD, D Kietzmann MD*, I Meineke PhD**, R Port MD§, A Hoeft MD
Pharmacokinetics Of Piritramide In Patients Undergoing Elective Surgery
|
Vladimir Piotrovskij, Eric Snoeck, Achiel Van Peer
Liarozole Population Pharmacokinetics At The Steady State
|
C Pobel* - D Breilh+ - M C Saux+ - S Demare* - J N Parola
A Population Pharmacokinetic Study Of Ciprofloxacine Penetration In To Lung Tissue
|
ML McFadyen, MPMajola, R Nair*, M Govender*, H Laher*
The Relationship Of Phenytoin Concentrations To Gingival Hyperplasia
|
Z Hussein, C J Eaves, D B Hutchinson & C J Canfield1
Population Pharmacokinetics Of Proguanil In Patients With Acute P Falciparum Malaria After Combined Therapy With Atovaquone
|
C.Pobel* - E.Chatelut+ - B.Tranchand x - J.N. Parola* - S.Demare*
Neural Network Prediction Of Dose And PP Parameters Values From A Population Approach Point Of View: Some Examples And Comments
|
M. Tod and J.M. Rocchisani
Comparison Of ED, EID, API And Bayesian-API Criteria For The Robust Optimisation Of Sampling Times In Pharmacokinetics.
|
